Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1583 participants
OBSERVATIONAL
2015-11-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
NCT02028676
Gathering Records to Evaluate Antiretroviral Treatment-South Africa
NCT04149782
Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection
NCT03800407
Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho
NCT02126696
Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV
NCT01529125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Children down-referred from DNH
This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
Data abstraction
The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
Tier.net
For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
Children LTF from DNH
This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
Data abstraction
The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
Tier.net
For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
Caregivers of LTF
This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
Tracing questionnaire
The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
DNH only
This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
Tier.net
For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data abstraction
The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
Tracing questionnaire
The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
Tier.net
For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Tracing Study:
* Legal caregiver (older than 18) a child who was included in the ART Outcomes Study that was found to be LTFU from DNH or from the down-referral facility.
Exclusion Criteria
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elaine J. Abrams, MD
Research Director, ICAP at Columbia University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elaine J Abrams, MD
Role: PRINCIPAL_INVESTIGATOR
ICAP at Columbia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chatty Clinic
Port Elizabeth, Eastern Cape, South Africa
Dora Nginza Hospital
Port Elizabeth, Eastern Cape, South Africa
Empilweni TB Hospital
Port Elizabeth, Eastern Cape, South Africa
Govan Mbeki Clinic
Port Elizabeth, Eastern Cape, South Africa
Joe Slovo Clinic
Port Elizabeth, Eastern Cape, South Africa
Kwadwesi Clinic
Port Elizabeth, Eastern Cape, South Africa
Kwazakhele Clinic
Port Elizabeth, Eastern Cape, South Africa
Kwazakhele Community Health Center
Port Elizabeth, Eastern Cape, South Africa
Motherwell Community Health Center
Port Elizabeth, Eastern Cape, South Africa
New Brighton Clinic
Port Elizabeth, Eastern Cape, South Africa
New Brighton Community Health Center
Port Elizabeth, Eastern Cape, South Africa
Soweto Clinic
Port Elizabeth, Eastern Cape, South Africa
Walmer 14th Avenue Clinic
Port Elizabeth, Eastern Cape, South Africa
West End Clinic
Port Elizabeth, Eastern Cape, South Africa
Zwide Clinic
Port Elizabeth, Eastern Cape, South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAO9854
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.